Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma

Source: Targeted Oncology, January 2021

Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-γ inhibitor, and nivolumab (Opdivo).

In the first study, updated findings from an expansion cohort of the ongoing phase 1/1b MARIO-1 trial (NCT02637531), presented during the 35th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2020)

READ THE ORIGINAL FULL ARTICLE
Menu